Comparative Pharmacokinetic Analysis of а Novel Prolonged Release Dosage Form of Lithium Citrate in Mice

This study assessed the comparative pharmacokinetics of a novel prolonged release dosage form of lithium citrate in white outbred mature mice - males after single intragastrically administration. In the experiment mice were divided into two groups (8-10 animals each group) which were received lithium citrate (LC) (75 mg/kg) or complex based on lithium citrate, aluminum oxide and organosilicone polymer (LCAS) (1120 mg/kg) once intragastrically. These doses were calculated based on lithium containing at the ratio 5,6 mg/kg. Pharmacokinetic parameters and relative bioavailability were calculated based on lithium ions concentration in serum and brain, which was measured by inductively-coupled plasma atomic emission spectrometry (ICP-AES). According to received pharmacological data of LCAS the Cmax of lithium ions in serum is lower by 4,3 times, than if administration of LC, relative bioavailability of LCAS is 44.41% of standard LC. Performed research has proven that combining aluminium oxide and organosilicone polymer as supportive components with lithium citrate helps to maintaining a stable lithium ions concentration in blood and brain which is important for achieving positive lithium therapy effect.